EMA’s Prime Designation for Roche’s RG6042 – to treat Huntington’s disease
Roche announced that the European Medicines Agency (EMA) has granted Prime (PRIority MEdicines) designation for the company’s investigational medicine RG6042 (formerly known... Read More
What is EMA’s PRIME designation?
The PRIME programme was launched by the EMA in 2016 to provide early and enhanced support to optimize the development of eligible... Read More